Pentameric ligand-gated ion channels (pLGICs) are membrane bound receptors found in the nervous system. They are responsible for detecting neurotransmitters released from neurons and subsequently mediating responses of the cells on which they are found. Thus, pLGICs play an invaluable role in communication between cells of the nervous system and understanding their function is pivotal to understanding how the nervous system works in general. One factor which is known to mediate pLGIC function is lipids found in the membrane environment in which pLGICs are embedded. This dissertation explores the various ways in which lipids interact with and modulate the function of pLGIC. Potential mechanisms and biological consequences of this modulation will be presented and discussed within the context of our current state of knowledge of pLGIC and nervous system function.

L’addiction à la nicotine est une pathologie qui concerne un tiers de la population adulte mondiale et qui est souvent associée avec d’autres troubles psychiatriques tels que la dépression, la schizophrénie ou encore les troubles liés au stress. Chaque année, près de 8 millions de personnes décèdent des conséquences de la consommation de tabac. Cette pathologie constitue la première cause de morts évitables dans le monde. Ce phénomène de dépendance au tabac est induit par la nicotine, principale substance addictive et psychoactive du tabac, qui va agir sur les récepteurs nicotiniques de l’acétylcholine (nAChR) et ainsi détourner le fonctionnement normal de différents circuits neuronaux. De manière aigüe, la nicotine agit directement sur les nAChR ce qui va globalement activer les réseaux neuronaux. A plus long terme, elle va induire une plasticité synaptique et perturber la transmission nicotinique endogène. La nicotine va notamment détourner le système dopaminergique, acteur majeur de l’apprentissage par renforcement, de la motivation et de l’évaluation de la récompense. Ces modifications neuronales conduisent non seulement au renforcement mais entrainent aussi une perturbation de différents traits comportementaux (prise de décision, exploration, vulnérabilité au stress, etc.). Ces relations entre symptômes et traits pourraient expliquer les fortes comorbidités observées entre la dépendance aux drogues d’abus, et particulièrement au tabac, et d’autres manifestations pathologiques telles que les troubles liés au stress. Au cours de cette thèse j’ai tout d’abord abordé les bases neurophysiologiques qui sous-tendent ces comorbidités, en proposant la dopamine comme un substrat commun aux effets du stress social, de la nicotine et des perturbations de la prise de décision associées (impulsivité, sensibilité à la récompense, évaluation du risque, etc.). J’ai pu montrer que l’augmentation de l’activité des neurones dopaminergiques observée après une exposition à la nicotine ou à un stress social est responsable des perturbations des comportements de choix chez la souris. En effet, nous avons pu reproduire ces altérations comportementales en élevant artificiellement le niveau d’activité des neurones dopaminergiques à l’aide de stimulations optogénétiques. La dissection des mécanismes par lesquels la nicotine détourne les circuits neuronaux se heurte aujourd’hui à un manque d’outils permettant une manipulation sélective, réversible et avec une résolution spatio-temporelle suffisante des acteurs moléculaires impliqués. Une deuxième partie de mon travail de thèse a consisté en l’implémentation in vivo chez la souris, de la pharmacologie optogénétique pour les nAChR. La photo-inhibition des nAChR contenant la sous-unité beta2 nous a permis de mettre en évidence l’impact de la modulation cholinergique endogène sur l’activité des neurones dopaminergiques. Nous avons pu, en outre, inhiber la réponse de ces mêmes neurones à l’injection intraveineuse aiguë de nicotine et le renforcement associé dans une tâche de préférence de place conditionnée pour la nicotine. / Nicotine addiction is a condition that affects one third of the world's adult population and is often associated with other psychiatric disorders such as schizophrenia, mood- and stress-related disorders. Every year, nearly 8 million people die from the consequences of tobacco use. This pathology is the leading cause of preventable death in the world. This phenomenon of tobacco dependence is induced by nicotine, the main addictive and psychoactive substance in tobacco, which acts on nicotinic acetylcholine receptors (nAChRs) and thus hijacks the normal functioning of various neuronal circuits. Acute nicotine directly acts on nAChRs and activates neural networks. In the longer term, it will induce synaptic plasticity and disrupt endogenous nicotinic transmission. In particular, nicotine disrupts the dopaminergic system, a key player in reinforcement learning, motivation and reward evaluation. These neural changes not only lead to reinforcement but also to a disruption of different behavioral traits such as decision-making, exploration, vulnerability to stress, etc. These relationships between symptoms and features could explain the strong comorbidities observed between substance abuse, and particularly tobacco addiction, and other pathologies such as stress-related disorders. During this thesis, I first addressed the neurophysiological bases underlying these comorbidities, by proposing dopamine as a common substrate for the effects of social stress, nicotine and associated decision-making disorders (impulsivity, reward sensitivity, risk assessment, etc.). I have shown that the increase in dopamine neuron activity observed after exposure to nicotine or social stress is responsible for disrupting choice behavior in mice. Indeed, we could reproduce these behavioral maladaptations by artificially increasing the activity level of dopaminergic neurons using optogenetic stimuli. The dissection of the mechanisms by which nicotine diverts neuronal circuits is currently hampered by a lack of tools for selective, reversible, spatially and temporally precise manipulation of the molecular players involved. A second part of my thesis work consisted in the in vivo implementation in mice of optogenetic pharmacology for nAChR. The photoinhibition of beta2-containing nAChRs revealed the impact of endogenous cholinergic modulation on the activity of dopaminergic neurons. We could optically inhibit the response of these same neurons to acute intravenous injection of nicotine and the associated reinforcement in a task of conditioned place preference for nicotine.

Basal Ganglia are evolutionarily conserved brain nuclei involved in several physiologically important animal behaviors like motor control and reward learning. Striatum, which is the input nuclei of basal ganglia, integrates inputs from several neurons, like cortical and thalamic glutamatergic input and local GABAergic inputs. Several neuromodulators, such as dopamine, accetylcholine and serotonin modulate the functional properties of striatal neurons. Aberrations in the intracellular signaling of these neurons lead to several debilitating neurodegenerative diseases, like Parkinson’s disease. In order to understand these aberrations we should first identify the role of different molecular players in the normal physiology. The long term goal of this research is to understand the molecular mechanisms responsible for the integration of different neuromodulatory signals by striatal medium spiny neurons (MSN). This signal integration is known to play important role in learning. This is manifested via changes in the synaptic weights between different neurons. The group of synpases taken into consideration for the current work is the corticostriatal one, which are synapses between the cortical projection neurons and MSNs. One of the molecular processes of considerable interest is the interaction between dopaminergic and cholinergic inputs. In this thesis I have investigated the interactions between the biochemical cascades triggered by dopaminergic, cholinergic (ACh) and glutamatergic inputs to the striatal MSN. The dopamine induced signaling increases the levels of cAMP in the striatonigral MSNs. The sources of dopamine and acetylcholine are dopaminergic neurons (DAN) from midbrain and tonically active cholinergic interneurons (TAN) of striatum, respectively. A sub-second burst activity in DAN along with a simultaneous pause in TAN is a characteristic effect elicited by a salient stimulus. This, in turn, leads to a dopamine peak and, possibly, an acetylcholine (ACh) dip in striatum. I have looked into the possibility of sensing this ACh dip and the dopamine peak at striatonigral MSNs. These neurons express D1 dopamine receptor (D1R) coupled to Golf and M4 Muscarinic receptor (M4R) coupled to Gi/o . These receptors are expressed significantly in the dendritic spines of these neurons where the Adenylate Cyclase 5 (AC5) is a point of convergence for these two signals. Golf stimulates the production of cAMP by AC5 whereas Gi/o inhibits the Golf mediated cAMP production. I have performed a kinetic-modeling exercise to explore how dopamine and ACh interacts with each other via these receptors and what are the effects on the downstream signaling events. The results of model simulation suggest that the striatonigral MSNs are able to sense the ACh dip via M4R. They integrate the dip with the dopamine peak to activate AC5 synergistically. We also found that the ACh tone may act as a potential noise filter against noisy dopamine signals. The parameters for the G-protein GTPase activity indicate towards an important role of GTPase Activating Proteins (GAPs), like RGS, in this process. Besides this we also hypothesize that M4R may have therapeutic potential. / <p>QC 20140325</p>

Electrical stimulation of the vagus nerve attenuates tumor necrosis factor (TNF) synthesis by macrophages and reduces the systemic inflammatory response. Current evidence suggests that the α7 nicotinic acetylcholine receptor present in the celiac/superior mesenteric ganglia is a key component in vagus nerve signaling to the spleen; however, there is currently no direct anatomical evidence that the α7 receptor is present in the murine celiac/superior mesenteric ganglia. Our study addresses this deficiency by providing anatomical evidence that the α7 receptor is expressed within the celiac/superior mesenteric ganglia and splenic nerve fibers using immunohistochemistry and quantitative polymerase chain reaction (qPCR). α7 receptor mRNA is highly expressed in the celiac/superior mesenteric ganglia and at low levels in the spleen compared to the brain. Double-labeling for α7 and tyrosine hydroxylase shows that α7 receptor protein is present on noradrenergic neurons within the ganglia and prejunctionally on noradrenergic nerve fibers within the spleen. The α7 receptor in the ganglia provides a possible location for the action of α7-selective agonists, while prejunctional α7 receptor expressed on splenic nerves may induce an increase in norepinephrine release in a positive feedback system enhanced by lymphocyte-derived acetylcholine.

While it is clear that most drugs of abuse act to increase extracellular dopamine levels in the nucleus accumbens (NAc), the molecular mechanisms mediating this process vary depending on the molecular target each drug acts on. The rewarding properties of most drugs of abuse including cocaine, amphetamine, and heroin have been well established for some time; however, the molecular mechanisms by which ethanol acts to mediate reward have not been fully elucidated. In this thesis, I have examined the role of nicotinic acetylcholine receptors (nAChRs), known molecular targets for nicotine addiction, in mediating the initial rewarding properties of alcohol. Using a mouse model of voluntary ethanol consumption called Drinking in the Dark (DID), in combination with nAChR pharmacology and mouse genetics, we have provided further evidence for the role of nAChRs in mediating the initial rewardingproperties of ethanol. Because of the vast number of possible functional nAChR subtypes present in the brain, I sought to investigate which subtype of nAChR may be responsible for ethanol reinforcement. To accomplish this, I used twocomplementary nAChR mouse models. The first is a knock-out line that does not express the α4 subunit (α4 KO) and the second is a knock-in line that expresses α4* nAChRs that are hypersensitive to agonist (Leu9′Ala). We have also shown, for the first time, that a specific nAChR subtype, those that contain the α4 subunit (α4*), mediate voluntary ethanol consumption and reward. Next, I examined the role of α4* nAChRs in modulating voluntary ethanol consumption after systemic administration of the FDA approved smoking cessation drug varenicline, a partial agonist of α4* nAChRs. We showed that varenicline and nicotine both reduced acute ethanol consumption in an α4* nAChR dependent mechanism. Taken together, our data indicate that activation of α4* nAChRs is necessary and sufficient for reduction of ethanol consumption and further supports the hypothesis that α4* nAChRs are molecular targets for alcohol cessation therapies.

No description available.

The spleen is a key participant in the pathophysiology of sepsis and inflammatory disease. Many splenocytes exhibit a cholinergic phenotype, but our knowledge regarding their cholinergic biology and how they are affected by sepsis is incomplete. We evaluated effects of acute sepsis on the spleen using the cecal ligation and puncture (CLP) model in C57BL/6 and ChATBAC-eGFP mice. Quantification of cholinergic gene expression showed that choline acetyltransferase and vesicular acetylcholine transporter (VAChT) are present and that VAChT is upregulated in sepsis, suggesting increased capacity for release of acetylcholine (ACh). High affinity choline transporter is not expressed but organic acid transporters are, providing additional mechanisms for release. Flow cytometry studies identified subpopulations of cholinergic T and B cells as well as monocytes/macrophages. Neither abundance nor GFP intensity of cholinergic T cells changed in sepsis, suggesting that ACh synthetic capacity was not altered. Spleens have low acetylcholinesterase activity, and the enzyme is localized primarily in red pulp, characteristics expected to favor cholinergic signaling. For cellular studies, ACh was quantified by mass spectroscopy using d4-ACh internal standard. Isolated splenocytes from male mice contain more ACh than females, suggesting the potential for gender-dependent differences in cholinergic immune function. Isolated splenocytes exhibit basal ACh release, which can be increased by isoproterenol (4 and 24 h) or by T cell activation with antibodies to CD3 and CD28 (24 h). Collectively, these data support the concept that sepsis enhances cholinergic function in the spleen and that release of ACh can be triggered by stimuli via different mechanisms.

Catharanthine is derived from the Catharanthus roseus plant and is an analog to ibogaine, a drug that reduces opioid and alcohol withdrawal symptoms and decreases drug self-administration in both animals and humans. Catharanthine has promise to be an alternative pharmacological treatment for addiction without the adverse side effects associated with ibogaine. The objective of this study was to evaluate catharanthine’s effects on dopamine (DA) transmission in the mesolimbic DA system as well as determine its effects on both ethanol withdrawal induced anxiety and drug-seeking behaviors in mice. We hypothesized that catharanthine would inhibit evoked DA release in the nucleus accumbens (NAc) while also reducing anxiety and drug seeking behaviors in mice. We found that superfusion of catharanthine (1-100 µM) to mouse brain slices significantly inhibits evoked DA release in the NAc of the striatum in a dose dependent manner, while also slowing DA reuptake through inhibition of the dopamine transporter (DAT), measured using fast-scan cyclic voltammetry (FSCV). We also found that intraperitoneal administration of catharanthine in live mice significantly increases extracellular DA, measured via microdialysis with electrochemical detection. Catharanthine inhibition of evoked DA release was significantly reduced by the non-selective nAChR antagonist mecamylamine, the α4 nAChR antagonist dihydro-β-erythroidine hydrobromide (DhβE) and the α6 nAChR antagonist α-conotoxin MII, suggesting that catharanthine inhibits α4 and α6 nAChRs in the NAc. Iontophoresis and in-vivo data indicates that catharanthine slows DA reuptake and increases extracellular DA in the NAc through partial inhibition of DATs. Catharanthine also blocked increases in anxiety-like behavior during ethanol withdrawal in mice in the elevated plus maze. Lastly, preliminary data suggests that catharanthine increases both water and ethanol drinking in a 24-hour two-bottle choice drinking paradigm, which was contrary to our hypothesis.

No description available.

Nicotine has been shown to enhance multiple forms of learning and memory. However the substrates through which these effects occur are not well understood. To examine the specific substrates of nicotine's acute effects on trace fear conditioning, I infused nicotine into areas thought to support trace fear conditioning, the dorsal hippocampus, ventral hippocampus and medial prefrontal cortex. Additionally, we investigated the contributions of nicotinic acetylcholinergic signaling to trace fear conditioning by infusing the nicotinic antagonists dihydro-beta-erythroidine (DHbE) and methyllycaconitine (MLA) into these areas. Nicotine had different effects on both trace and contextual fear conditioning depending on dose and brain region, as did the nicotinic antagonists. In the dorsal hippocampus nicotine infusion enhanced both trace and contextual conditioning, although these effects were dissociable by dose and training protocol. Additionally, the high-affinity nicotinic antagonist DHbE produced selective deficits in trace conditioning, suggesting that while enhancement of nicotinic signaling can affect both contextual and trace learning, nicotinic activity in the dorsal hippocampus is critically involved in trace but not contextual conditioning. In the ventral hippocampus nicotine infusion produced deficits in both trace and contextual fear conditioning, without affecting delay conditioning, while the antagonists had no effect. This finding suggests that altered nicotinic signaling in the ventral hippocampus can suppress hippocampus dependent learning. In the mPFC nicotine selectively enhanced trace conditioning though both antagonists also enhanced trace fear conditioning. Unlike in the mPFC or dorsal hippocampus, where nicotine and antagonist induced effects occurred during training, effects in the ventral hippocampus occurred at both training and testing, suggesting that the ventral hippocampus may be able to modulate acquisition as well as expression of hippocampus dependent learning. Additionally, antagonist infusion into the mPFC during testing produced deficits in expression, suggesting that this area can modulate fear expression. Thus, the substrates of nicotinic acetylcholinergic contributions to trace and contextual fear conditioning are diverse. I put forth a multi-component model of these contributions, where trace fear conditioning is supported by dorsal hippocampus dependent maintenance of the CS during the trace interval, long-term storage in the mPFC and ventral hippocampal mediated acquisition and expression. / Psychology